trending Market Intelligence /marketintelligence/en/news-insights/trending/3w1yN4vtPqnbW2qYhF1S_A2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Australis Capital to acquire Folium Biosciences in all-stock deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Australis Capital to acquire Folium Biosciences in all-stock deal

Australis Capital Inc. agreed to acquire Folium Biosciences LLC, a private manufacturer and distributor of cannabinoids, in an all-stock deal.

On completion, current members of Folium will own 89% of Australis Capital. Australis Capital, a venture capital firm that invests in cannabis and real estate, will rebrand as Folium Biosciences before the transaction.

Las Vegas-based Australis Capital plans to seek shareholder approval for the proposed transaction in the future.